Kindred Biosciences (NASDAQ:KIN) has been given a $10.00 target price by equities research analysts at HC Wainwright in a research report issued to clients and investors on Tuesday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s target price points to a potential upside of 33.33% from the company’s current price.

A number of other research analysts have also issued reports on the stock. B. Riley set a $11.00 price target on shares of Kindred Biosciences and gave the company a “buy” rating in a research note on Tuesday. ValuEngine upgraded shares of Kindred Biosciences from a “sell” rating to a “hold” rating in a research note on Friday. Finally, Zacks Investment Research lowered shares of Kindred Biosciences from a “buy” rating to a “hold” rating in a research note on Wednesday, October 11th. Three equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. Kindred Biosciences presently has a consensus rating of “Buy” and a consensus price target of $9.63.

Kindred Biosciences (NASDAQ:KIN) traded down $0.10 during midday trading on Tuesday, hitting $7.50. 85,800 shares of the company traded hands, compared to its average volume of 144,079. Kindred Biosciences has a 1 year low of $3.90 and a 1 year high of $9.65.

Kindred Biosciences (NASDAQ:KIN) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.04. analysts forecast that Kindred Biosciences will post -1.18 earnings per share for the current year.

Several large investors have recently added to or reduced their stakes in KIN. Nationwide Fund Advisors acquired a new stake in shares of Kindred Biosciences in the second quarter worth $100,000. JPMorgan Chase & Co. acquired a new stake in shares of Kindred Biosciences in the second quarter worth $119,000. Trexquant Investment LP acquired a new stake in shares of Kindred Biosciences in the second quarter worth $120,000. SG Americas Securities LLC acquired a new stake in shares of Kindred Biosciences in the third quarter worth $123,000. Finally, OxFORD Asset Management LLP acquired a new stake in shares of Kindred Biosciences in the second quarter worth $128,000. Hedge funds and other institutional investors own 66.85% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Kindred Biosciences (KIN) Given a $10.00 Price Target by HC Wainwright Analysts” was originally reported by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was illegally copied and republished in violation of international copyright & trademark laws. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/12/05/kindred-biosciences-kin-given-a-10-00-price-target-by-hc-wainwright-analysts.html.

Kindred Biosciences Company Profile

Kindred Biosciences, Inc is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products.

Analyst Recommendations for Kindred Biosciences (NASDAQ:KIN)

Receive News & Ratings for Kindred Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.